Myungmoon Pharm Co., Ltd. (017180) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Myungmoon Pharm Co., Ltd. (017180:KRX), powered by AI.

Current Price
₩1,320
P/E Ratio
23.6
Market Cap
44.8B
Sector
Healthcare
What is the Myungmoon Pharm Co., Ltd. stock price forecast?

Myungmoon Pharm Co., Ltd. is currently trading at ₩1,320. View real-time AI analysis on Alpha Lenz.

What is Myungmoon Pharm Co., Ltd. insider trading activity?

View the latest insider trading data for Myungmoon Pharm Co., Ltd. on Alpha Lenz.

What is Myungmoon Pharm Co., Ltd.'s P/E ratio?

Myungmoon Pharm Co., Ltd.'s P/E ratio is 23.6.

Myungmoon Pharm Co., Ltd.

KRX · 017180
₩1,320-7(-0.53%)Market closedKRX regular session 09:00–15:30 KST
Ask about Myungmoon Pharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Myungmoon Pharm Co., Ltd. trades at a P/E of 23.6 (fair value) with modest ROE of 1.9%.

Ask for details

Company Overview

Myungmoon Pharm Co., Ltd. is a pharmaceutical company that plays a significant role in the healthcare and medical sectors. The primary function of Myungmoon Pharm is to research, develop, and market various pharmaceutical products ranging from prescription medications to over-the-counter remedies. The company is committed to advancing medical science and improving patient care by delivering innovative and effective health solutions. Myungmoon Pharm focuses on a diverse array of therapeutic areas, including cardiovascular health, metabolic disorders, and central nervous system conditions, among others. The company's operations extend beyond domestic borders, impacting global healthcare through international partnerships and distribution networks. By leveraging advanced research methodologies and cutting-edge technology, Myungmoon Pharm is at the forefront of pharmaceutical innovation. In the financial markets, Myungmoon Pharm Co., Ltd. holds significance due to its contributions to the rapidly evolving pharmaceutical industry. Investors and analysts closely watch the company's developments, as they may influence both healthcare advancements and market dynamics. With its dedication to improving healthcare outcomes, Myungmoon Pharm Co., Ltd. remains a pivotal entity in the pharmaceutical landscape.

CEO배철한
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees291

Company Statistics

FY 2025

Profile

₩44,818,559,280Market Cap
₩195,247,096,550Revenue
33.95MShares Out
291Employees

Margins

54.76%Gross
5.97%EBITDA
3.50%Operating
1.36%Pre-Tax
0.73%Net

Valuation

23.65P/E
0.45P/B
0.23EV/Sales
12.30EV/EBITDA
-5.25P/FCF

Growth (CAGR)

8.67%Rev 3Yr
8.84%Rev 5Yr
2.03%Op Inc 3Yr
N/AOp Inc 5Yr
-43.77%Net Inc 3Yr
N/ANet Inc 5Yr

Returns

0.53%ROA
1.94%ROE
2.92%ROIC

Financial Health

₩5,835,761,790Cash & Cash Equivalents
₩162,162,987,960Net Debt
160.83%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Myungmoon Pharm Co., Ltd. (ticker: 017180) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 291 employees. Market cap is $44.8B.

The current price is ₩1,320 with a P/E ratio of 23.65x and P/B of 0.45x.

ROE is 1.94% and operating margin is 3.50%. Annual revenue is $195.2B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Myungmoon Pharm Co., Ltd. (017180) Stock Forecast 2026 ₩1,320 — Price, Financials & Analyst Targets | Alpha Lenz